Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?

Ann Oncol. 2005 Oct;16(10):1709. doi: 10.1093/annonc/mdi325. Epub 2005 Sep 8.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Female
  • Gefitinib
  • Humans
  • Patient Selection
  • Quinazolines / administration & dosage
  • Reproducibility of Results
  • Trastuzumab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Quinazolines
  • Trastuzumab
  • Gefitinib